NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Featured here, the Cash Flow Statement for Traws Pharma Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each ...

At close: June 11 at 4:00:00 PM EDT ...

Big Pharma Stocks Retail Stocks Subscriptions Alpha Picks Premium & Pro About Premium Explore Alpha Picks Search field ... TRAW Traws Pharma, Inc. Stock Price & Overview Follow $1.66 0.01 (+0.61% ...

ReShape Lifesciences Inc RSLS fell 12.5% to $2.72 in pre-market trading. ReShape Lifesciences jumped over 35% on Thursday ...

Save time with instant access to analyst-curated, pharma-specific data, deep industry and disease research, and analytical and forecasting tools – all in one place. Learn from research and ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American Association for Cancer Research (AACR) annual meeting 2025 in Chicago ...